Trials / Completed
CompletedNCT02252250
Transanal Total Mesorectal Excision Versus Laparoscopic TME for Rectal Cancer
A Prospective Cohort Study of Transanal Laparoscopic Total Mesentery Excision Versus Conventional Laparoscopic Surgery for Rectal Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Third Military Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive surgery toal mesentery excision for rectal cancer.
Detailed description
Natural orifice transluminal endoscopic surgery (NOTES) give the opportunity to reduce surgical access trauma leading to a more painless surgery and enhancing a fast postoperative recovery. Experience with transanal minimal invasive surgery(TAMIS) for rectal cancer show that such NOTES procedures are feasible and safe. And also, lots of experimental studies and small case series reporting the feasibility of transanal anterior resection with single incision laparoscopic surgery(SILS) port or other devices. However any prospective feasibility study demonstrating the safety of the procedure and functional outcomes (sphincter function, sexual function, QOF) are missing. This study investigates the feasibility, practicability, safety and subjective as well as functional outcome of transanal minimal invasive total mesentery excision for rectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | conventional laparoscopic total mesentery excision | conventional laparoscopic total mesentery excision |
| PROCEDURE | transanal hybrid-laparoscopic total mesentery excision | transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA. |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2019-10-01
- Completion
- 2020-11-01
- First posted
- 2014-09-30
- Last updated
- 2023-11-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02252250. Inclusion in this directory is not an endorsement.